Rezolute, Inc. shares rise 2.42% intraday after announcing presentation of participant baseline data from Phase 3 study.

Rezolute, Inc. rose 2.42% in intraday trading, with the company announcing that an abstract titled 'Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress' has been selected for a late-breaking presentation at ENDO 2025. The presentation is expected to offer important insights into the population and its characteristics, which could be seen as a positive development for the company's ongoing research and clinical trials.